Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Cellectar Biosciences合作消息 - Cellectar Biosciences宣布与American Oncology Network (AON)和Meaningful Insights-BioTech Analytics (MiBA)合作，共同推进Waldenstrom's macroglobulinemia (WM)治疗[1] - AON是一个快速增长的社区肿瘤学实践网络，与Cellectar的合作是为了识别WM患者的未满足需求，并优化iopofosine I 131的潜在商业推出[4] Cellectar Biosciences研究结果 - Cellectar Biosciences的iopofosine I 131在关键研究中取得积极的结果，显示出61%的主要反应率(MRR)[2]